Patents by Inventor Jan Munch
Jan Munch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240190918Abstract: The present invention relates to a fibril peptide consisting of a sequence of from 8 to 20 amino acids and wherein said fibril peptide comprises the amino acid sequence RTIFIISM or a sequence at least 75% identical thereto. The present invention further relates to a method of delivering a cargo comprised in a particle into a host cell, comprising a) contacting said host cell with said particle and with a fibril peptide according to any one of claims 1 to 8; and, thereby b) delivering said cargo into said host cell; and to uses, kits, and devices related thereto.Type: ApplicationFiled: March 29, 2022Publication date: June 13, 2024Inventors: Jan Münch, Desiree Schütz, Lena Rauch
-
Publication number: 20210122771Abstract: In various embodiments new molecular tweezers compounds are provided. The compounds described herein (e.g., molecular tweezers) are believed to be useful for inhibiting protein aggregation (or disaggregating aggregated proteins). In certain embodiments the compounds described herein (e.g., molecular tweezers) are believed to be useful in the treatment of pathologies characterized by protein aggregation (e.g., amyloidopathies), and/or in the treatment of brain or spinal cord damage associated with acute trauma, stroke, and the like, and/or in the treatment of lysosomal storage diseases, and/or in the treatment of lipofuscin-related disorders, and in various viral infections.Type: ApplicationFiled: June 28, 2019Publication date: April 29, 2021Inventors: Gal Bitan, Thomas Schrader, Jan Münch, Christian Heid, Andrea Sowislok, Annika Röcker, Danielle Bouquio, Ravinder Malik
-
Patent number: 10294272Abstract: A peptide effective in blocking the CXC-chemokine receptor 4 (CXCR4) mediated HIV-1 NL4-3 (X4-tropic) infection with an IC50 value of less than 50 ?M.Type: GrantFiled: June 12, 2014Date of Patent: May 21, 2019Assignee: Pharis Biotec GmbHInventors: Wolf-Georg Forssmann, Frank Kirchhoff, Jan Münch, Ludger Ständker
-
Publication number: 20160122389Abstract: A peptide effective in blocking the CXC-chemokine receptor 4 (CXCR4) mediated HIV-1 NL4-3 (X4-tropic) infection with an IC50 value of less than 50 ?M.Type: ApplicationFiled: June 12, 2014Publication date: May 5, 2016Inventors: Wolf-Georg Forssmann, Frank Kirchhoff, Jan Münch, Ludger St ndker
-
Patent number: 9045563Abstract: A peptide having the following amino acid sequence: Z1-LVRYTKKVPQVSTPTL-Z2(ALB-408) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of ALB408-423; wherein Z represents number of from 0 to 10 amino acid residues.Type: GrantFiled: July 3, 2008Date of Patent: June 2, 2015Assignee: PHARIS BIOTECH GMBHInventors: Wolf-Georg Forssmann, Frank Kirchhoff, Jan Münch, Ludger Ständker
-
Patent number: 8652483Abstract: The invention relates to a peptide derived from HIV-1 gp120 which forms insoluble aggregates when introduced into an aqueous solution and its use for enhancing viral infection of cells. In addition, the invention comprises methods for enhancing viral infection of cells, for concentrating a virus and for separating a virus from a fluid.Type: GrantFiled: November 16, 2011Date of Patent: February 18, 2014Inventors: Jan Münch, Frank Kirchhoff, Maral Yolamanova
-
Publication number: 20130029902Abstract: A peptide having the following amino acid sequence: Z1-LVRYTKKVPQVSTPTL-Z2(ALB-408) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of ALB408-423; wherein Z represents number of from 0 to 10 amino acid residues.Type: ApplicationFiled: July 3, 2008Publication date: January 31, 2013Inventors: Wolf-Georg Forssmann, Frank Kirchhoff, Jan Münch, Ludger Ständker
-
Patent number: 8299031Abstract: Subject of the invention are peptides corresponding to a fragment of amino acids 240-290 of human prostatic acid phosphatase. The invention also relates to nucleic acids, antibodies, medicaments and diagnostics and their use and use of the peptides for the treatment and diagnosis of viral diseases, especially HIV disease.Type: GrantFiled: January 25, 2007Date of Patent: October 30, 2012Assignee: Viro Pharmaceuticals GmbH & Co. KGInventors: Ludger Ständker, Wolf-Georg Forssmann, Knut Adermann, Jan Münch, Frank Kirchhoff, Elke Rücker
-
Publication number: 20120122177Abstract: The invention relates to a peptide derived from HIV-1 gp120 which forms insoluble aggregates when introduced into an aqueous solution and its use for enhancing viral infection of cells. In addition, the invention comprises methods for enhancing viral infection of cells, for concentrating a virus and for separating a virus from a fluid.Type: ApplicationFiled: November 16, 2011Publication date: May 17, 2012Inventors: Jan MÜNCH, Frank KIRCHOFF, Maral YOLAMANOVA
-
Patent number: 7741287Abstract: The present invention relates to the use of a peptide having the amino acid sequence NH2-VCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH-COOH (SEQ ID NO:1) as well as variants, derivatives and fragments of the peptide for the treatment of viral diseases.Type: GrantFiled: August 16, 2005Date of Patent: June 22, 2010Assignee: IPF PharmaCeuticals GmbHInventors: Wolf-Georg Forssmann, Frank Kirchhoff, Jan Münch, Ludger Ständker
-
Patent number: 7655629Abstract: The invention relates to peptides with biological activity against infection having the amino acid sequence Z1-LE-X1-IP-X2-X3-X4-P-X5-X6-X7-X8-X9-X10-K-X11-X12-X13-X14-X15-Z2, wherein X1 is a lysine, alanine, or aspartic acid; X2 is a cysteine, methionine or isoleucine; X3 is a serine, cysteine, lysine or glycine; X4 is an isoleucine, alanine, phenylalanine or cysteine; X5 is a proline, D-proline or a substituted L- or D-proline; X6 is a cysteine or glutamic acid; X7 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X8 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X9 is an amino acid with an aromatic side chain; X10 is a glycine, alanine or asparagine; X11 is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X12 is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X13 is an amino acid with a hydrophobic or an aromatic side chain; X14 is aType: GrantFiled: December 19, 2003Date of Patent: February 2, 2010Assignee: IPF Pharmaceuticals GmbHInventors: Knut Adermann, Frank Kirchhoff, Jan Münch, Axel Schulz
-
Publication number: 20090191206Abstract: Subject of the invention are peptides corresponding to a fragment of amino acids 240-290 of human prostatic acid phosphatase. The invention also relates to nucleic acids, antibodies, medicaments and diagnostics and their use and use of the peptides for the treatment and diagnosis of viral diseases, especially HIV disease.Type: ApplicationFiled: January 25, 2007Publication date: July 30, 2009Applicant: VIRO PHARMACEUTICALS GMBH & CO. KGInventors: Ludger Ständker, Wolf-Georg Forssmann, Knut Adermann, Jan Münch, Frank Kirchhoff, Elke Rücker
-
Publication number: 20080312144Abstract: The present invention relates to the use of a peptide having the amino acid sequence NH2-VCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH-COOH as well as variants, derivatives and fragments of the peptide for the treatment of viral diseases.Type: ApplicationFiled: August 16, 2005Publication date: December 18, 2008Applicant: IPF PharmaCeuticals GmbHInventors: Wolf-Georg Forssmann, Frank Kirchhoff, Jan Munch, Ludger Standker
-
Publication number: 20070123465Abstract: The invention relates to oligomeric peptides with biological activity against HIV infection having the amino acid sequence (Z1-LE-X1-IP—X2—X3—X4—P—X5—X6—X7—X8—X9—X10—K—X11—X12—X13—X14—X15-Z2)n, wherein n indicates the number of monomeric peptide chains, whereby n is 2, 3 or 4; X1 is a lysine, alanine, or aspartic acid; X2 is a cysteine, methionine or isoleucine; X3 is a serine, cysteine, lysine or glycine; X4 is an isoleucine, alanine, phenylalanine or cysteine; X5 is a proline, D-proline or a substituted L- or D-proline; X6 is a cysteine or glutamic acid; X7 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X8 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X9 is an amino acid with an aromatic side chain; X10 is a glycine, alanine or asparagine; X11 is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X12 is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydType: ApplicationFiled: June 17, 2005Publication date: May 31, 2007Applicant: IPF PHARMACEUTICALS GMBHInventors: Knut Adermann, Frank Kirchhoff, Jan Munch, Axel Schulz, Wolf-Georg Forssmann
-
Publication number: 20070072805Abstract: The invention relates to peptides with biological activity against infection having the amino acid sequence Z1-LE-X1-IP-X2-X3-X4-P-X5-X6-X7-X8-X9-X10-K-X11-X12-X13-X14-X15-Z2, wherein X1 is a lysine, alanine, or aspartic acid; X2 is a cysteine, methionine or isoleucine; X3 is a serine, cysteine, lysine or glycine; X4 is an isoleucine, alanine, phenylalanine or cysteine; X5 is a proline, D-proline or a substituted L- or D-proline; X6 is a cysteine or glutamic acid; X7 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X8 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X9 is an amino acid with an aromatic side chain; X10 is a glycine, alanine or asparagine; X11 is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X12 is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X13 is an amino acid with a hydrophobic or an aromatic side chain; X14 is aType: ApplicationFiled: December 19, 2003Publication date: March 29, 2007Inventors: Knut Andermann, Frank Kirchhoff, Jan Munch, Axel Schulz
-
Patent number: 7037896Abstract: A peptide having the following amino acid sequence: Z1-LEAIPMSIPPEVKFNKPFVF-Z2 (VIRIP) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, polyethylene glycol (PEG) modified, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of VIRIP; wherein Z1 and Z2 are independently a sequence of from 0 to 10 amino acid residues, and if Z1 or Z2=zero amino acid residues, then Z1=H and/or Z2=COOH.Type: GrantFiled: November 8, 2000Date of Patent: May 2, 2006Assignee: IPF PharmaCeuticals GmbHInventors: Frank Kirchhoff, Jan Münch, Ludger Ständker, Wolf-Georg Forssmann